Skip to main content
رجوع
SHJBF logo

Shanghai Junshi Biosciences Co., Ltd.

جودة البيانات: 100%
ذروة شراء
SHJBF
OTC Healthcare Biotechnology
KWD 3.00
KWD 0.00 (0.00%)
القيمة السوقية: 4.34B
نطاق اليوم
KWD 3.00 KWD 3.00
نطاق 52 أسبوعًا
KWD 1.97 KWD 4.23
حجم التداول
1,000
متوسط 50 يوم / 200 يوم
KWD 3.00 / KWD 2.99
الإغلاق السابق
KWD 3.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -5.1 0.4
P/B 0.7 2.9
ROE % -14.3 3.8
Net Margin % -35.0 3.9
Rev Growth 5Y % -11.8 10.0
D/E 0.7 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2028 -KWD 0.122
-KWD 0.126 – -KWD 0.117
5.2 B 1
FY2027 -KWD 0.222
-KWD 0.230 – -KWD 0.213
4.1 B 1
FY2026 -KWD 0.523
-KWD 0.543 – -KWD 0.503
3.3 B 1

النقاط الرئيسية

Revenue declined -11.82% annually over 5 years
Negative free cash flow of -1.21B
PEG of 0.72 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 36.75%
Capital intensive — 30.75% of revenue goes to capex

النمو

Revenue Growth (5Y)
-11.82%
Revenue (1Y)24.93%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-14.30%
ROIC-6.70%
Net Margin-35.00%
Op. Margin-37.37%

الأمان

Debt / Equity
0.69
Current Ratio1.60
Interest Coverage-12.37

التقييم

P/E Ratio
-5.09
P/B Ratio0.72
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 24.93% Revenue Growth (3Y) 27.27%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -11.82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.43B Net Income (TTM) -851.83M
ROE -14.30% ROA -6.88%
Gross Margin 72.34% Operating Margin -37.37%
Net Margin -35.00% Free Cash Flow (TTM) -1.21B
ROIC -6.70% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.69 Current Ratio 1.60
Interest Coverage -12.37 Dividend Yield 0.00%
Valuation
P/E Ratio -5.09 P/B Ratio 0.72
P/S Ratio 1.78 PEG Ratio 0.72
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 4.34B Enterprise Value 5.86B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.43B 1.95B 1.50B 1.45B 4.02B
Net Income -851.83M -1.28B -2.28B -2.39B -718.56M
EPS (Diluted) -0.84 -1.30 -2.32 -2.60 -0.81
Gross Profit 1.76B 1.45B 835.26M 927.21M 2.77B
Operating Income -909.47M -1.30B -2.45B -2.75B -592.71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12.39B 10.80B 11.36B 12.56B 11.05B
Total Liabilities 6.16B 4.85B 4.02B 2.78B 2.72B
Shareholders' Equity 6.03B 5.88B 7.17B 9.48B 7.96B
Total Debt 4.14B 2.93B 1.79B 1.32B 628.20M
Cash & Equivalents 2.62B 2.49B 3.78B 6.00B 3.50B
Current Assets 4.46B 4.28B 5.55B 7.22B 5.83B
Current Liabilities 2.78B 2.53B 2.48B 1.77B 2.02B